CClinicalTrials.gg
CompletedNCT03411642CONTESTUpdated Sep 13, 2023Results posted

Comparative Effectiveness Study of Transthoracic and Transesophageal Echocardiography in Stroke

An observational study in Stroke, Acute, sponsored by Universitätsklinikum Hamburg-Eppendorf. Completed at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
494
Ages
18 Years and older
Sex
All
01

Study summary

The Comparative Effectiveness Study of Transthoracic and Transesophageal Echocardiography in Stroke (CONTEST) aims at assessing the diagnostic value of transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE) with regards to treatment consequences in patients with acute ischemic stroke.

Read the detailed description

For this purpose, the investigators will perform a prospective multicenter diagnostic comparative effectiveness study. Patients with acute stroke will be studied by both TTE and TEE. Patients with already defined stroke etiology and determined secondary prevention will be excluded from the trial. Treatment relevant diagnostic findings will be identified by a central endpoint adjudication committee. In order to demonstrate a hypothesized 2% absolute increase in the number of treatment relevant diagnostic findings by TEE as compared to TTE, 880 stroke patients will be enrolled in six German stroke centers. CONTEST will allow answering the question whether and for which group of stroke patients TEE is indicated in addition to TTE. By this, the study will provide evidence to guide justified recommendations for echocardiography in acute stroke patients.

02

Conditions studied

  • Stroke, Acute

Browse trials for

Keywords

  • Stroke, echocardiography
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute stroke in whom echocardiography is indicated will be studied by TTE and TEE.

Inclusion criteria

  • acute ischemic stroke or transitory ischemic attack (TIA)
  • age ≥18 years
  • informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients with already defined stroke etiology and determined secondary prevention treatment strategy prior to echocardiography (e.g. atrial fibrillation, carotid artery stenosis, cervical artery dissection)
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
494 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Number of Participants With Diagnostic Findings That Lead to a Change in Acute Treatment or Treatment for Secondary Prevention

    Treatment relevant diagnostic findings identified by a central endpoint adjudication committee comprising both cardiologists and neurologists.

    Time frame: Inpatient treatment on a stroke unit usually <7 days

Secondary outcomes

  1. Number of Patients With Change of Assessment of Stroke Etiology After TEE

    Number of patients with change in the assessment of stroke etiology (cardioembolism, large artery atherosclerosis, small vessel disease, other determined etiology, unknown etiology) after performing TEE

    Time frame: Inpatient treatment on a stroke unit usually <7 days

06

Results

Posted Sep 13, 2023

Participant flow

Participant flow — Overall Study
MilestonePatients Included
Started494
Participants who received tte492
Participants who received tee454
Completed454
Not completed40

Outcome measures

PrimaryNumber of Participants With Diagnostic Findings That Lead to a Change in Acute Treatment or Treatment for Secondary Prevention

Treatment relevant diagnostic findings identified by a central endpoint adjudication committee comprising both cardiologists and neurologists.

Time frame:
Inpatient treatment on a stroke unit usually <7 days
Reported as:
Count of participants · Participants
Number of Participants With Diagnostic Findings That Lead to a Change in Acute Treatment or Treatment for Secondary Prevention
ParticipantsPatients Studied With Both TTE and TEE
Treatment relevant findings in TTE — Yes64
Treatment relevant findings in TTE — No390
Treatment relevant findings in TEE — Yes86
Treatment relevant findings in TEE — No368
SecondaryNumber of Patients With Change of Assessment of Stroke Etiology After TEE

Number of patients with change in the assessment of stroke etiology (cardioembolism, large artery atherosclerosis, small vessel disease, other determined etiology, unknown etiology) after performing TEE

Time frame:
Inpatient treatment on a stroke unit usually <7 days
Reported as:
Count of participants · Participants
Number of Patients With Change of Assessment of Stroke Etiology After TEE
ParticipantsPatients Studied With Both TTE and TEE
Yes52
No401
Missing data1

Adverse events

Collected over In-patient treatment on a stroke unit usually <7 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Receiving TTE0/492 (0%)0/492 (0%)0/492 (0%)
Patients Receiving TEE0/454 (0%)0/454 (0%)0/454 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patients Included
Mean64.7 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Patients Included
Female204
Male290
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Patients Included
Region of Enrollment
Region of Enrollment(participants)Patients Included
Germany494
Diagnosis (acute ischemic stroke, transient ischemic attack, retinal ischemia)
Diagnosis (acute ischemic stroke, transient ischemic attack, retinal ischemia)(Participants)Patients Included
Acute ischemic stroke385
Transient ischemic attack89
Retinal ischemia20
07

Study locations

4 sites
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Albertinen-Krankenhaus
    Hamburg, 22457, Germany
  • Regio Klinikum Pinneberg
    Pinneberg, 25421, Germany
  • Kreiskliniken Reutlingen
    Reutlingen, 72764, Germany
08

References and documents

Publications

  • Thomalla G, Upneja M, Camen S, Jensen M, Schroder J, Barow E, Boskamp S, Ostermeier B, Kissling S, Leinisch E, Tiburtius C, Clausen H, Cheng B, Blankenberg S, Nedelmann M, Steinbrecher A, Andres F, Rosenkranz M, Sinning C, Schnabel RB, Gerloff C. Treatment-Relevant Findings in Transesophageal Echocardiography After Stroke: A Prospective Multicenter Cohort Study. Stroke. 2022 Jan;53(1):177-184. doi: 10.1161/STROKEAHA.121.034868. Epub 2021 Sep 9. PubMed 34496617 ↗

Study documents

  • Protocol and statistical analysis plan · Jan 16, 2016

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03411642
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
Albertinen Krankenhaus, Regio Kliniken, Helios University Hospital Wuppertal, Kreiskliniken Reutlingen, Klinikum Karlsbad-Langensteinbach
Responsible party
Sponsor
First posted
Jan 26, 2018
Start date
Jul 1, 2017
Primary completion
Jun 30, 2019
Completion
Aug 31, 2019
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Study contacts

Götz Thomalla, MD
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion